VIMRx
Executive Summary
Alfonso Tobia, PhD, most recently senior director-pharmacology at the R.W. Johnson Pharmaceutical Research Institute, joins Stamford, Conn. antiviral drug development firm as VP-R&D. He will be responsible for the clinical development of hypericin for the treatment of HIV and blood product safety. VIMRx holds exclusive worldwide rights to hypericin, which was initially developed at the Weizmann Institute and New York University Medical Center